Rituximab Plus CHOP in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: An Update of the GELA Study
ByBertrand Coiffier, MD, PhD,C. Fermé,Olivier Hermine, MD, PhD,C. Haioun,E. Baumelou,P. Solal-Celigny,A. Delmer,C. Sebban,N. Mounier,G. Tertian,A. Van Hoof,A. Bosly
Published: | Updated:
At the 2000 Annual Meeting of the American Society of Hematology, we presented the benefits of rituximab (Rituxan) combined with CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone), known as R-CHOP, in comparison with CHOP alone for the treatment of elderly patients with diffuse large B-cell lymphoma (DLCL).